Antianginal Efficacy of Ranolazine When Added to Treatment With Amlodipine. The ERICA (Efficacy of Ranolazine in Chronic Angina) Trial

Journal of the American College of Cardiology

Volumn 48, Issue 3, 2006, Pages 566-575

  Stone, Peter H ^a   Gratsiansky, Nikolay A ^b   Blokhin, Alexey ^c   Huang, I Zu ^a   Meng, Lixin ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Institute of Physicochemical Medicine   (Russian Federation)

^c CV Therapeutics ^*

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ANTIANGINA PECTORIS AGENT; ANTIDIABETIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLYCERYL TRINITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOSORBIDE MONONITRATE; NITRIC ACID DERIVATIVE; PLACEBO; RANOLAZINE;

ADD ON THERAPY; ADULT; AGED; ANGINA PECTORIS; ARTICLE; ATRIOVENTRICULAR BLOCK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FEMALE; FUNCTION TEST; HEART INFARCTION; HEART VENTRICLE EXTRASYSTOLE; HEMODYNAMICS; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTICENTER STUDY; NAUSEA; PERIPHERAL EDEMA; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SINUS BRADYCARDIA; SINUS TACHYCARDIA; STATISTICAL SIGNIFICANCE; STROKE; TORSADE DES POINTES; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

AGED; AMLODIPINE; ANGINA PECTORIS; CHRONIC DISEASE; CORONARY DISEASE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NITROGLYCERIN; PIPERAZINES; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 33746192571     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2006.05.044     Document Type: Article

References (27)

1. American Heart Association. Heart Disease and Stroke Statistics-2005 Update (2005), American Heart Association, Dallas, TX
2. Abrams J. Clinical practice. Chronic stable angina. N Engl J Med 352 (2005) 2524-2533
3. Gibbons R.J., Abrams J., Chatterjee K., et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina. a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 41 (2003) 159-168
4. Holubkov R., Laskey W.K., Haviland A., et al. Angina 1 year after percutaneous coronary intervention. a report from the NHLBI Dynamic Registry. Am Heart J 144 (2002) 826-833
5. Serruys P.W., Unger F., Sousa J.E., et al. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 344 (2001) 1117-1124
6. Dargie H., Ford I., Fox K.M., and TIBET Study Group. Total Ischaemic Burden European Trial (TIBET). Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina. Eur Heart J 17 (1996) 104-112
7. Emanuelsson H., Ahlstrom P., Kujacic V., et al. Felodipine versus placebo in stable effort-induced angina pectoris in patients inadequately controlled with metoprolol-a dose-finding study. J Cardiovasc Pharmacol 24 (1994) 303-309
8. Ronnevik P.K., Silke B., and Ostergaard O. Felodipine in addition to beta-adrenergic blockade for angina pectoris. A multicentre, randomized, placebo-controlled trial. Eur Heart J 16 (1995) 1535-1541
9. Siu S.C., Jacoby R.M., Phillips R.T., and Nesto R.W. Comparative efficacy of nifedipine gastrointestinal therapeutic system versus diltiazem when added to beta blockers in stable angina pectoris. Am J Cardiol 71 (1993) 887-892
10. Packer M. Drug therapy. Combined beta-adrenergic and calcium-entry blockade in angina pectoris. N Engl J Med 320 (1989) 709-718
11. Strauss W.E., and Parisi A.F. Combined use of calcium-channel and beta-adrenergic blockers for the treatment of chronic stable angina. Rationale, efficacy, and adverse effects. Ann Intern Med 109 (1988) 570-581
12. Thadani U. Treatment of stable angina. Curr Opin Cardiol 14 (1999) 349-358
13. Tolins M., Weir E.K., Chesler E., and Pierpont G.L. "Maximal" drug therapy is not necessarily optimal in chronic angina pectoris. J Am Coll Cardiol 3 (1984) 1051-1057
14. Antzelevitch C., Belardinelli L., Zygmunt A.C., et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 110 (2004) 904-910
15. Wu L., Shryock J.C., Song Y., Li Y., Antzelevitch C., and Belardinelli L. Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome. J Pharmacol Exp Ther 310 (2004) 599-605
16. Belardinelli L., Antzelevitch C., and Fraser H. Inhibition of late (sustained/persistent) sodium current. a potential drug target to reduce intracellular sodium-dependent calcium overload and its detrimental effects on cardiomyocyte function. Eur Heart J 6 Suppl I (2004) I13-I17
17. Chaitman B.R., Skettino S.L., Parker J.O., et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol 43 (2004) 1375-1382
18. Rousseau M.F., Pouleur H., Cocco G., and Wolff A.A. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris. Am J Cardiol 95 (2005) 311-316
19. Pepine C.J., Wolff A.A., and Ranolazine Study Group. A controlled trial with a novel antiischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents. Am J Cardiol 84 (1999) 46-50
20. Chaitman B.R., Pepine C.J., Parker J.O., et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina. a randomized controlled trial. JAMA 291 (2004) 309-316
21. Cocco G., Rousseau M.F., Bouvy T., et al. Effects of a new metabolic modulator, ranolazine, on exercise tolerance in angina pectoris patients treated with beta-blocker or diltiazem. J Cardiovasc Pharmacol 20 (1992) 131-138
22. Reed J.F. Contributions to two-sample statistics. J Appl Statistics 32 (2005) 37-44
23. Koch G.G., Catherin M.T., Jung J.W., and Amara I.A. Issues for covariance analysis of dichotomous and ordered categorical data from randomized clinical trials and nonparametric strategies for addressing them. Appendix VII. Stat Med (1998) 1863-1892
24. Asirvatham S., Sebastian C., and Thadani U. Choosing the most appropriate treatment for stable angina. Safety considerations. Drug Saf 19 (1998) 23-44
25. Pfizer. Norvasc. Amlodipine (1990), Pfizer, New York, NY
26. Rehnqvist N., Hjemdahl P., Billing E., et al. Effects of metoprolol vs. verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm (APSIS). Eur Heart J 17 (1996) 76-81
27. Heidenreich P.A., McDonald K.M., Hastie T., et al. Meta-analysis of trials comparing beta-blockers, calcium antagonists, and nitrates for stable angina. JAMA 281 (1999) 1927-1936